首页> 外文会议>Nihon To?seki Igakkai., Gakujutsu Shu?kai So?kai >Targets and Therapeutics for Glycemic Control in Diabetes Patients on Hemodialysis
【24h】

Targets and Therapeutics for Glycemic Control in Diabetes Patients on Hemodialysis

机译:血液透析糖尿病患者血糖控制的靶向和治疗方法

获取原文

摘要

Background: For diabetes patients without nephropathy, glycemic control is important to reduce the risk or delay the progression of diabetes complications, including nephropathy. In diabetes patients on hemodialysis, good glycemic control is necessary to improve prognosis. Many factors influence the blood glucose level of diabetes patients on hemodialysis, such as factors associated with end-stage kidney disease and factors related to hemodialysis. Therefore, since glucose metabolism in diabetes patients on hemodialysis has unique characteristics, it is necessary to manage blood glucose in these patients with specific guidelines. Here, we describe the targets and therapeutics for glycemic control in diabetes patients on hemodialysis. Summary: According to the guidelines of the Japanese Society for Dialysis Therapy (JSDT) regarding the treatment of diabetes in hemodialysis patients, the target casual plasma glucose level (predialysis blood glucose level) is less than 180-200 mg/dL, the target glycated albumin value is less than 20.0% (less than 24.0% in patients at risk of hypoglycemia). When glycemic control is poor and the plasma glucose level before dialysis is high, hemodial-ysis-induced hyperglycemia may occur, in which plasma glucose decreases during hemodialysis and appears to rise after hemodialysis. On the other hand, hemodialysis patients with diabetes tend to develop hypoglycemia due to various factors. In addition, autonomic nervous system disorders may complicate the manifestation of hypoglycemia so that these patients may not exhibit symptoms. Thus, particular caution is necessary to prevent hypoglycemia. Key Messages: The plasma glucose level of hemodialysis patients with diabetes may fluctuate under the influence of many factors, such as the state of kidney function, delay in metabolism and excretion of diabetes medicine, and hemodialysis parameters. In particular, patients with poor glycemic control are susceptible to various influences, leading to a widerfluctuation in plasma glucose, with increased risk of both hyperglycemia and hypoglycemia. Since hypoglycemia may lead to a poorer prognosis and quality of life, it is necessary to control plasma glucose levels with the aim of improving the prognosis while avoiding hypoglycemia.
机译:背景:对于没有肾病的糖尿病患者,血糖控制对于降低风险或延迟糖尿病并发症的进展非常重要,包括肾病。在糖尿病患者血液透析患者中​​,良好的血糖控制是改善预后所必需的。许多因素会影响血液透析患者糖尿病患者的血糖水平,例如与血液透析相关的因素相关的因素。因此,由于糖尿病患者对血液透析患者具有独特的特征,因此有必要在这些患者中管理这些患者的血糖。在这里,我们描述了血液透析患者糖尿病患者血糖控制的目标和治疗方法。摘要:根据日本透析治疗(JSDT)对血液透析患者糖尿病治疗的指导方针,目标休闲血浆葡萄糖水平(预血糖血糖水平)小于180-200mg / dl,妊娠期糖类白蛋白的值小于20.0%(低血糖风险的患者患者少于24.0%)。当血糖控制较差并且透析前的血浆葡萄糖水平高,可能发生血液摩擦诱导的高血糖,其中血浆葡萄糖在血液透析期间减少,血液透析后似乎升高。另一方面,由于各种因素,糖尿病患者患有糖尿病患者往往会发生低血糖。此外,自主神经系统疾病可能使低血糖的表现复杂化,使这些患者可能不会表现出症状。因此,特别小心是必要的,以防止低血糖。关键消息:糖尿病血糖患者的血浆葡萄糖水平可能会在许多因素的影响下波动,例如肾功能状态,糖尿病药物的代谢延迟和血液透析参数。特别地,血糖控制差的患者易受各种影响,导致血浆葡萄糖中越越来越多,具有高血糖和低血糖的风险增加。由于低血糖可能导致预后和生活质量较差,因此有必要控制血浆葡萄糖水平,目的是提高预后,同时避免低血糖。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号